PHARMAC funds longer-acting treatments for haemophilia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2019 Category: Drugs & Pharmacology Source Type: news
Enzyre Appoints Dirk Pollet as Chief Executive Officer
Awarded 2M grant and completes seed financing to develop high-precision point-of-care Hemophilia Biochip device
NIJMEGEN, Netherlands, April 30, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyre, which is developing breakthrough ambulant diagno... Diagnostics, Personnel Enzyre , Hemophilia Biochip (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2019 Category: Pharmaceuticals Source Type: news
St. Jude prepares to launch global hemophilia gene therapy trial
St. Jude is trying to establish a gene therapy program to bring next-level treatment options to patients in under-resourced countries. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 23, 2019 Category: Biotechnology Authors: Jason Bolton Source Type: news
St. Jude prepares to launch global hemophilia gene therapy trial
St. Jude is trying to establish a gene therapy program to bring next-level treatment options to patients in under-resourced countries. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 23, 2019 Category: American Health Authors: Jason Bolton Source Type: news
Cameroon: World Hemophilia Day - Population Schooled On Treatment Mechanisms
[Cameroon Tribune] Sensitisation activities to commemorate the day end today in Yaounde. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 18, 2019 Category: African Health Source Type: news
Roche reports a strong start in 2019 and raises the outlook for the full-year
In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra. (Source: World Pharma News)
Source: World Pharma News - April 18, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe
On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. (Source: World Pharma News)
Source: World Pharma News - April 17, 2019 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news
Gene-based factor VIIa prevents bleeding episodes in animals with hemophilia
(Children's Hospital of Philadelphia) Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in animals may set the stage for a new therapy for a subset of patients with hemophilia who now develop antibodies to the standard maintenance treatment and then require on-demand 'bypass' therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news
Cochrane's 30 under 30: Ndi Euphrasia Ebai-Atuh
Cochrane is made up of 13,000 members and over 50,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Cochrane is an incredible community of people who all play their part in improving health and healthcare globally. We believe that by putting trusted evidence at the heart of health decisions we can achieve a world of improved health for all. Many of our contributors are young people working with Cochrane as researchers, citizen scientists...
Source: Cochrane News and Events - April 12, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news
European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Media News)
Source: Roche Media News - March 14, 2019 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Investor Update)
Source: Roche Investor Update - March 14, 2019 Category: Pharmaceuticals Source Type: news
Roche to buy Spark Therapeutics
Roche Holding has entered a definitive merger agreement with Spark Therapeutics, as the Swiss drugmaker seeks to expand its ability to treat rare diseases through gene therapies, as well as build its hemophilia portfolio. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 25, 2019 Category: Pharmaceuticals Source Type: news
Roche to buy gene therapy specialist Spark in $4.3 billion deal
Roche Holding AG said on Monday it will buy Spark Therapeutics in a $4.3 billion deal, as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
FDA OKs Turoctocog Alfa Pegol (Esperoct) for Hemophilia A FDA OKs Turoctocog Alfa Pegol (Esperoct) for Hemophilia A
Turoctocog alfa pegol is an extended half-life factor VIII molecule for treatment and prophylaxis of bleeding episodes and perioperative management in adults and children with hemophilia A.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
Bagsværd, Denmark, 19 February 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Esperoct for the treatment of adults and children with hemophilia A.
Esperoct... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2019 Category: Drugs & Pharmacology Source Type: news
